Arvinas (ARVN) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ARVN Stock Alerts $34.80 -0.43 (-1.22%) (As of 03:03 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 27 at 8:39 AM | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Shares Sold by Neuberger Berman Group LLCNeuberger Berman Group LLC trimmed its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 40.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,754 shares of the company's stock after selling 38,876 sharMay 26 at 7:12 AM | marketbeat.comTrexquant Investment LP Invests $2.52 Million in Arvinas, Inc. (NASDAQ:ARVN)Trexquant Investment LP purchased a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 61,243 shares of the company's stock, valued at approximately $May 25 at 8:22 AM | americanbankingnews.comArvinas (NASDAQ:ARVN) Shares Down 4.7% May 23, 2024 | globenewswire.comArvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual CongressMay 23, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Stock Price Down 4.7%Arvinas (NASDAQ:ARVN) Trading Down 4.7%May 23, 2024 | finance.yahoo.comIt Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The MicroscopeMay 22, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Trading 6.7% Higher Arvinas (NASDAQ:ARVN) Trading Up 6.7%May 22, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Shares Sold by Brown Advisory Inc.Brown Advisory Inc. reduced its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 39.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 265,431 shares of the company's stock after sMay 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Holding Company on Strong Clinical Trial Results and Competitive Market PositioningMay 19, 2024 | americanbankingnews.comArvinas (NASDAQ:ARVN) Earns Buy Rating from HC WainwrightMay 18, 2024 | marketbeat.comBNP Paribas Financial Markets Buys 97,661 Shares of Arvinas, Inc. (NASDAQ:ARVN)BNP Paribas Financial Markets grew its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 98.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 197,052 shares of the company's stock after purchasing an addMay 17, 2024 | markets.businessinsider.comBuy Rating on Arvinas for Promising Breast Cancer Therapy and Market PotentialMay 17, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $87.00 price target on shares of Arvinas in a research report on Friday.May 16, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Shares Gap Up to $32.33Arvinas (NASDAQ:ARVN) Shares Gap Up to $32.33May 16, 2024 | markets.businessinsider.comArvinas, Pfizer, Report 6-month Follow Up Data From Phase 1b Study Of Vepdegestrant+PalbociclibMay 16, 2024 | globenewswire.comArvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)May 16, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have received an average rating of "Moderate Buy" from the sixteen brokerages that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and fourteen have issued a buy recMay 15, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Trading 6.6% Higher Arvinas (NASDAQ:ARVN) Trading Up 6.6%May 13, 2024 | marketbeat.comInternational Assets Investment Management LLC Invests $2.20 Million in Arvinas, Inc. (NASDAQ:ARVN)International Assets Investment Management LLC purchased a new position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 53,508 shares of the company's stock, valuedMay 11, 2024 | finance.yahoo.comArvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 10, 2024 | marketbeat.comArvinas, Inc. Expected to Post Q2 2024 Earnings of $1.09 Per Share (NASDAQ:ARVN)Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Analysts at HC Wainwright cut their Q2 2024 EPS estimates for Arvinas in a research report issued on Wednesday, May 8th. HC Wainwright analyst A. Fein now forecasts that the company will earn $1.09 per share for the quarter, down from their previous forMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Arvinas with Promising Trial Updates and Robust Financial OutlookMay 9, 2024 | globenewswire.comArvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressMay 9, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Price Target Lowered to $60.00 at Wells Fargo & CompanyWells Fargo & Company decreased their price target on shares of Arvinas from $63.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday.May 9, 2024 | marketbeat.comLos Angeles Capital Management LLC Buys Shares of 27,889 Arvinas, Inc. (NASDAQ:ARVN)Los Angeles Capital Management LLC purchased a new position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 27,889 shares of the company's stock, valued at approximatelyMay 8, 2024 | markets.businessinsider.comStrong Buy Recommendation for Arvinas Holding Company on Innovative Pipeline and Strategic PartnershipsMay 8, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Price Target Cut to $68.00 by Analysts at Stifel NicolausStifel Nicolaus cut their price objective on shares of Arvinas from $72.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday.May 8, 2024 | finance.yahoo.comWe Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business GrowthMay 8, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Posts Quarterly Earnings ResultsArvinas (NASDAQ:ARVN - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.45. Arvinas had a negative return on equity of 70.24% and a negative net margin of 185.09%. The firm had revenue of $25.30 million during the quarter, compared to the consensus estimate of $32.94 million. During the same quarter in the previous year, the business earned ($1.54) earnings per share. The firm's quarterly revenue was down 22.2% compared to the same quarter last year.May 7, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Trading 6.8% Higher Arvinas (NASDAQ:ARVN) Stock Price Up 6.8%May 7, 2024 | investorplace.comARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | globenewswire.comArvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 30, 2024 | theglobeandmail.comAs Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up ResponseApril 26, 2024 | investing.comArvinas appoints new chief business officerApril 26, 2024 | finanznachrichten.deArvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerApril 26, 2024 | marketbeat.comFederated Hermes Inc. Has $5.68 Million Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN)Federated Hermes Inc. lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 32.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 138,028 shares of the company's stock after buying an additional 33,770 shares during the quaApril 24, 2024 | globenewswire.comArvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerApril 20, 2024 | finance.yahoo.comArvinas, Inc. (ARVN)April 20, 2024 | marketbeat.comInternational Assets Investment Management LLC Buys Shares of 53,508 Arvinas, Inc. (NASDAQ:ARVN)International Assets Investment Management LLC bought a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 53,508 shares of thApril 19, 2024 | marketbeat.comVontobel Holding Ltd. Takes $2.72 Million Position in Arvinas, Inc. (NASDAQ:ARVN)Vontobel Holding Ltd. bought a new position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 66,000 shares of the company's stock, valued at approximately $2,717,000. Vontobel Holding Ltd. ownedApril 16, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Short Interest UpdateArvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 8,600,000 shares, a growth of 8.6% from the March 15th total of 7,920,000 shares. Based on an average daily volume of 735,200 shares, the days-to-cover ratio is currently 11.7 days.April 12, 2024 | marketbeat.comHC Wainwright Lowers Arvinas (NASDAQ:ARVN) Price Target to $87.00HC Wainwright decreased their price objective on Arvinas from $90.00 to $87.00 and set a "buy" rating for the company in a report on Friday.April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth PotentialApril 11, 2024 | investors.comBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsApril 11, 2024 | markets.businessinsider.comArvinas Enters Deal With Novartis For License Of ARV-766, Sale Of AR-V7 Program; Stock JumpsApril 11, 2024 | globenewswire.comArvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerApril 11, 2024 | marketbeat.comSG Americas Securities LLC Lowers Stake in Arvinas, Inc. (NASDAQ:ARVN)SG Americas Securities LLC lowered its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 83.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,456 shares of the company's stock after selling 32,052 shares during the period. SG Americas SecApril 6, 2024 | marketbeat.comVanguard Group Inc. Buys 90,426 Shares of Arvinas, Inc. (NASDAQ:ARVN)Vanguard Group Inc. increased its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 2.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,608,223 shares of the company's stock after acquiring an additional 90,426 shares dMarch 29, 2024 | marketbeat.comWellington Management Group LLP Decreases Stock Position in Arvinas, Inc. (NASDAQ:ARVN)Wellington Management Group LLP lessened its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 44.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 76,163 shares of the company's stock after selling 61,087 shares during the period. WellingMarch 25, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Stock Rating Reaffirmed by Truist FinancialTruist Financial reaffirmed a "buy" rating and issued a $65.00 target price on shares of Arvinas in a research note on Monday. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Log Into Marc's $5,000 System Today (Ad)New Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. ARVN Media Mentions By Week ARVN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARVN News Sentiment▼1.030.92▲Average Medical News Sentiment ARVN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARVN Articles This Week▼103▲ARVN Articles Average Week Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RYTM News Today SNDX News Today MORF News Today AKRO News Today PLRX News Today ANNX News Today ENTA News Today ROIV News Today ELAN News Today ASND News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARVN) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden replacement revealed?Paradigm Press[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
